Teva Launches #Laugh4Lungs Social Media Campaign in Recognition of World COPD Day 2015

Teva Launches #Laugh4Lungs Social Media Campaign in Recognition of World COPD Day 2015

Campaign Uses Social Video to Raise Awareness for Chronic Obstructive Pulmonary Disease (COPD)

Amsterdam, 11th November, 2015 – Teva Pharmaceutical Industries Ltd. today announced the launch of the #Laugh4Lungs campaign. This social media campaign aims to use the power of laughter to promote global awareness of chronic obstructive pulmonary disease (COPD) and to raise money for three leading COPD charities across Europe, including: the British Lung Foundation (UK), Longfonds (Netherlands) and Fundación Lovexair (Spain).  #Laugh4Lungs is being launched in recognition of World COPD Day, which takes place on 18th November 2015.

COPD is a debilitating lung disease that is estimated to affect over 200 million people worldwide. Although COPD represents the fourth most common cause of death globally, awareness of COPD among the general public and those at greatest risk for the disease remains surprisingly low. As such, it is likely that many more individuals are living with COPD, but are yet to be diagnosed.

"At Teva we believe it is important to increase global awareness of this debilitating disease," said Luca Frangoni, Head of Respiratory, Teva Europe. "With #Laugh4Lungs we have chosen laughter as the vehicle to promote awareness of COPD because it's a universal language that transcends between all ages and is beneficial for lung function and overall wellbeing."

#Laugh4Lungs aims to inspire people to use the power of laughter to raise awareness and money for COPD, and to remind those living with COPD that they aren't alone. The campaign encourages people to share videos of themselves or someone else laughing on social media channels, then tag or nominate others within their social networks. In addition, people can also donate money to charities that are working to make a difference within the COPD community.

Please visit www.ICanLiveWithCOPD.com for more information about #Laugh4Lungs and how to donate, as well as further resources and practical advice about living with COPD.

About COPD
COPD is an umbrella term used to describe a group of debilitating diseases that cause progressive obstruction of the airways, including bronchitis and emphysema. Symptoms include breathlessness, frequent coughing, wheezing and chest tightness. COPD is commonly caused by smoking (active and passive), but other causes include exposure to air pollution, dust or fumes. COPD cannot be cured, but symptoms can be managed by taking medication, quitting smoking and living a healthy lifestyle. If the disease isn't managed properly, it can be fatal. More than three million people died of COPD in 2012, and The World Health Organisation (WHO) has predicted that COPD will become the most common cause of death by 2030.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (including competition from orally-administered alternatives, as well as from generic equivalents such as the recently launched Sandoz product) and our ability to continue to migrate users to our 40 mg/mL version and maintain patients on that version; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities (such as our pending acquisitions of Allergan's generic business and Rimsa), or to consummate and integrate acquisitions; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission.
# # #

IR Contacts:

Kevin C. Mannix        

United States                

(215) 591-8912

Ran Meir

United States

(215) 591-3033

Tomer Amitai             

Israel                    

972 (3) 926-7656

 

 

PR Contacts:

Iris Beck Codner

Israel             

972 (3) 926-7687

Denise Bradley

United States

(215) 591-8974

Nancy Leone

United States

(215) 284-0213 

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.